Immunitybio Inc (IBRX)
11.55
+0.00%
Immunitybio Inc (IBRX) is currently trading at $11.55. This represents a gain of 0% from the previous session. With a market capitalization of $11.39B, IBRX is a key component of the Health Care sector. Investors looking to trade IBRX should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade IBRX commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Immunitybio Inc (IBRX) shows a bullish trend. Analysts are watching the 0.00 level closely.
Fundamentals
Mkt Cap11.39B
P/E Ratio0.0000
Volume1,734,270
60-Day Technical Chart
Advanced Charting
Need more indicators for IBRX? Use the world's #1 platform.
Open IBRX on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $12
| Metric |
IBRX +0.00% |
OWL +0.00% |
ONDS +0.00% |
HONE -1.79% |
|---|---|---|---|---|
| Price | $11.55 | $10.73 | $10.40 | $12.10 |
| Mkt Cap | $11.39B | $16.68B | $4.40B | $26.07B |
| - | View → | View → | View → |
Latest Headlines
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance (NASDAQ:IBRX)
Seeking Alpha • Feb 25, 2026
$IBRX stock is up 3% today. Here's what we see in our data.
Quiver Quantitative • Feb 24, 2026
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
Stocktwits • Feb 24, 2026
Why ImmunityBio (IBRX) Is Up 65.3% After ANKTIVA’s European Approval And New Regional Partnerships
simplywall.st • Feb 24, 2026
IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook
Meyka • Feb 25, 2026
● Gemini Agentic AI Analyst Insight for IBRX
Market Education
- How can Retail Traders not lose money to Institutional Traders Jul 15, 2023
- What do these rich Traders do - Peek into their day Jul 15, 2023
- Canada Pension Plan - Top Stocks Nov 20, 2023
External Research